drugset / Trial / NCT07785830

A Clinical Trial to Evaluate the Effects of MK-4646 on Rosuvastatin in Healthy Participants (MK-4646-007)

NCT07785830 ↗

Phase 1 Not yet recruiting 16 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverOpen-labelBasic science

Summary

Researchers are looking for new treatments for people living with HIV-1 (Human Immunodeficiency Virus Type 1). HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. MK-4646 is a trial medicine designed to treat HIV-1. Before giving a trial medicine to people with a health condition, researchers first do studies in healthy participants. The goals of this trial are to learn: * What happens to rosuvastatin in a participant's body over time when it is taken with MK-4646 * About the safety of MK-4646 when taken with rosuvastatin and if people tolerate it. Tolerate means participants will receive trial medicine in the trial unless they need to stop it due to health problems.

Timeline

Start
2026-09-25
Primary completion
2026-11-10
Completion
2026-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-4646 Unknown — Oral
Subject Rosuvastatin Small molecule — Oral

Indications

No indication recorded.